Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.
Hong Kong-listed healthcare/nursing services company; specific service line not confirmed with confidence.
Moat: none
Headquarters: Hong Kong · Employees: 467
Size Fameglow (3774.HK) is a Hong Kong Health Care company (Medical/Nursing Services) with a market value of $4.54B, the 265th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$43.46 on 18 Nov 2026.
Growth Revenue grew 35.5% over the last twelve months (peer median +11.7%); the operating margin is 11.1% (peer median 9.0%).
Valuation It trades at 60.4× enterprise value to sales against a peer median of 2.2× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 57% a year for seven years (Req g). Recent delivered growth is +48%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 19.7 points above its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$590M | HK$590M | HK$435M | HK$299M | HK$228M |
| Revenue growth | — | +35% | +45% | +32% | — |
| Gross profit | HK$219M | HK$218M | HK$170M | HK$122M | HK$78.7M |
| EBITDA | HK$146M | HK$146M | HK$114M | HK$90.6M | HK$64.3M |
| Net income | HK$54.6M | HK$54.6M | HK$45.7M | HK$40.8M | HK$16.4M |
| Free cash flow | n/a | HK$45.1M | HK$26.2M | HK$18.3M | HK$38.1M |
| Capital expenditure | n/a | HK$68.1M | HK$53.4M | HK$13.5M | HK$32.2M |
| Total debt | n/a | HK$119M | HK$92.4M | HK$45.5M | HK$66.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3774.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +45.5% | +2.8% | highest of 21 |
| Distance from 52-week high | -7.8% | -12.9% | 6th highest of 21 |
| Revenue growth (TTM) | +35.5% | +11.7% | 2nd highest of 21 |
| Operating margin | 11.1% | 9.0% | 8th highest of 21 |
| EV / Sales | 60.4× | 2.2× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 57.4% | 12.7% | most demanding of 18 |
| Growth delivered (Del g) | +48.4% | +13.2% | 2nd highest of 18 |
| Hurdle (Req g minus delivered) | +9.0 pp | -1.5 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +19.7 pp | -0.2 pp | 2nd highest of 21 |
| Net debt / EBITDA | 0.1× | 2.9× | 5th least indebted of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fameglow 3774.HK | Hong Kong | $4.54B | n/a | +36% | 11% | 60.4× | 57.4% | +48.4% |
| BillionToOne BLLN | United States | $4.37B | +7% | +72% | 10% | 9.1× | 22.8% | +71.9% |
| Option Care Health OPCH | United States | $4.75B | +43% | +4% | 6% | 1.0× | 2.0% | +13.2% |
| Hims & Hers Health HIMS | United States | $4.00B | -26% | +30% | -1% | 1.7× | n/a | n/a |
| Lifestance Health LFST | United States | $5.24B | +79% | +23% | 6% | 3.3× | 33.4% | +30.4% |
| Concentra Group Holdings Parent CON | United States | $5.31B | +65% | +12% | 17% | 3.2× | 3.6% | +7.9% |
| Medicover MCOV-B.ST | Sweden | $3.87B | +21% | +3% | 7% | 2.0× | 19.6% | +20.2% |
| RadNet RDNT | United States | $5.66B | +32% | +21% | 5% | 3.1× | 38.8% | +13.7% |
| Dr. Lal PathLabs LALPATHLAB.NS | India | $3.53B | +15% | +17% | 24% | 10.4× | 32.3% | +11.8% |
| Acadia Healthcare ACHC | United States | $3.49B | +56% | +4% | 10% | 1.8× | n/a | n/a |
| Sonic Healthcare SHL.AX | Australia | $6.87B | +6% | +14% | 9% | 1.4× | 9.1% | +3.5% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 2.2× | 4.2% | +5.7% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 1.3× | -4.4% | +2.0% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 1.4× | 7.7% | +10.2% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 1.5× | 4.0% | +13.2% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 2.5× | 21.1% | +14.6% |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 2.8× | 38.0% | +3.9% |
| DaVita DVA | United States | $10.2B | -18% | +6% | 15% | 1.7× | -2.5% | +3.4% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 2.9× | n/a | n/a |
| Ensign ENSG | United States | $10.7B | +3% | +17% | 9% | 2.2× | 12.7% | +16.5% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 7.8× | 43.0% | +26.9% |